Research prototype, not medical advice.
Claims › C-0219-dq-pilot-physical-function-infl
In an open pilot trial (14 patients with pulmonary fibrosis), D+Q improved physical function and was feasible.
Confidence Debated
Level of evidence ●●●●●○ Randomized clinical trial
Observed in Human
Mission Map of aging (12 hallmarks)
Concepts Chronic inflammation Dasatinib + quercetin (D+Q) Idiopathic pulmonary fibrosis Senescence-associated secretory phenotype (SASP)
What the sources say
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).